| Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia G Saglio, DW Kim, S Issaragrisil, P Le Coutre, G Etienne, C Lobo, ... New England Journal of Medicine 362 (24), 2251-2259, 2010 | 2097 | 2010 |
| The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts Experts in Chronic Myeloid Leukemia Blood, The Journal of the American Society of Hematology 121 (22), 4439-4442, 2013 | 655 | 2013 |
| Essential role of patient blood management in a pandemic: a call for action A Shander, SM Goobie, MA Warner, M Aapro, E Bisbe, ... Anesthesia & Analgesia 131 (1), 74-85, 2020 | 196 | 2020 |
| Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus) HB Feys, J Roodt, N Vandeputte, I Pareyn, S Lamprecht, ... Blood, The Journal of the American Society of Hematology 116 (12), 2005-2010, 2010 | 134 | 2010 |
| The management of tuberculous pericardial effusion: experience in 233 consecutive patients H Reuter, LJ Burgess, VJ Louw, AF Doubell Clinics Cardiv Publishing, 2007 | 106 | 2007 |
| A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO … E Verburgh, R Achten, VJ Louw, C Brusselmans, M Delforge, ... Leukemia 21 (4), 668-677, 2007 | 99 | 2007 |
| Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide … P Sonneveld, R Hajek, A Nagler, A Spencer, J Bladé, T Robak, ... Cancer 112 (7), 1529-1537, 2008 | 84 | 2008 |
| Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study M Mohty, E Terpos, MV Mateos, M Cavo, S Lejniece, M Beksac, ... Clinical Lymphoma Myeloma and Leukemia 18 (10), e401-e419, 2018 | 77 | 2018 |
| Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment J Bladé, P Sonneveld, JF San Miguel, HJ Sutherland, R Hajek, A Nagler, ... Clinical Lymphoma and Myeloma 8 (6), 352-355, 2008 | 72 | 2008 |
| Effectiveness of the Ad26. COV2. S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study LG Bekker, N Garrett, A Goga, L Fairall, T Reddy, N Yende-Zuma, ... The Lancet 399 (10330), 1141-1153, 2022 | 61 | 2022 |
| Thromboembolic events in the South African Ad26. COV2. S vaccine study S Takuva, A Takalani, N Garrett, A Goga, J Peter, V Louw, J Opie, ... New England Journal of Medicine 385 (6), 570-571, 2021 | 57 | 2021 |
| Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome J Bladé, P Sonneveld, JF San Miguel, HJ Sutherland, R Hajek, A Nagler, ... Clinical Lymphoma Myeloma and Leukemia 11 (1), 44-49, 2011 | 56 | 2011 |
| Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis JP Smedema, VJ Louw Cardiovascular Journal of South Africa 18 (2), 84, 2007 | 44 | 2007 |
| Multiple myeloma treatment strategies with novel agents in 2011: a European perspective H Ludwig, M Beksac, J Bladé, J Cavenagh, M Cavo, M Delforge, ... Oncologist 16 (4), 388, 2011 | 43 | 2011 |
| Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines W Chen, A Leiter, YIN DONG, M Meiring, VJ Louw, HP Koeffler International journal of oncology 37 (3), 737-743, 2010 | 43 | 2010 |
| Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkins Lymphoma A Hellmann, S Rule, J Walewski, O Shpilberg, H Feng, H van de Velde, ... Clinical pharmacokinetics 50 (12), 781-791, 2011 | 42 | 2011 |
| Experience with adjunctive corticosteriods in managing tuberculous pericarditis H Reuter, LJ Burgess, VJ Louw, AF Doubell Clinics Cardiv Publishing, 2006 | 41* | 2006 |
| Making patient blood management the new norm(al) as experienced by implementors in diverse countries A Hofmann, DR Spahn, H Anke-Peggy, PBMI Group BMC Health Services Research 21 (1), 634, 2021 | 40 | 2021 |
| Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis K Antel, J Oosthuizen, F Malherbe, VJ Louw, MP Nicol, G Maartens, ... BMC infectious diseases 20, 1-8, 2020 | 32 | 2020 |
| International Foundation of Patient Blood Management (IFPBM) and Society for the Advancement of Blood Management (SABM) Work Group. Essential role of patient blood management … A Shander, SM Goobie, MA Warner, M Aapro, E Bisbe, ... Anesth Analg 131 (1), 74-85, 2020 | 31 | 2020 |
Estelle VerburghHaematologist, University of Cape TownVerified email at uct.ac.za
